Ørnbjerg, Lykke MidtbøllRugbjerg, KathrineGeorgiadis, StylianosRasmussen, Simon HorskjærJacobsson, LennartLoft, Anne GitteIannone, FlorenzoFagerli, Karen MindeVencovsky, JiriSantos, Maria JoséMöller, BurkhardPombo-Suarez, ManuelRotar, ZigaGudbjornsson, BjornCefle, AyseEklund, KariCodreanu, CatalinJones, Garethvan der Sande, MarleenWallman, Johan KarlssonSebastiani, MarcoMichelsen, BrigitteZávada, JakubNissen, Michael JohnSanchez-Piedra, CarlosTomšič, MatijaLove, Thorvardur JonRelas, HeikkiMogosan, CorinaHetland, Merete LundØstergaard, Mikkel2024-11-182024-11-182024-04-01Ørnbjerg, L M, Rugbjerg, K, Georgiadis, S, Rasmussen, S H, Jacobsson, L, Loft, A G, Iannone, F, Fagerli, K M, Vencovsky, J, Santos, M J, Möller, B, Pombo-Suarez, M, Rotar, Z, Gudbjornsson, B, Cefle, A, Eklund, K, Codreanu, C, Jones, G, van der Sande, M, Wallman, J K, Sebastiani, M, Michelsen, B, Závada, J, Nissen, M J, Sanchez-Piedra, C, Tomšič, M, Love, T J, Relas, H, Mogosan, C, Hetland, M L & Østergaard, M 2024, 'Patient-reported outcomes and PRO remission rates in 12,262 biologic-naïve patients with psoriatic arthritis treated with TNF-inhibitors in routine care', The Journal of rheumatology, vol. 51, no. 4, pp. 378–389. https://doi.org/10.3899/jrheum.2023-07640315-162XORCID: /0000-0003-0016-7591/work/153542684https://hdl.handle.net/2164/24635On behalf of the EuroSpA Scientific Committee, the authors acknowledge Novartis Pharma AG and IQVIA for supporting the EuroSpA Research Collaboration Network124090047engepidemiologyfatiguepainpsoriatic arthritistumor necrosis factor inhibitorsR MedicineSupplementary Datahttps://www.jrheum.org/highwire/filestream/45020/field_highwire_adjunct_files/0/2023-0764DataSuppl.pdfRJournal article10.3899/jrheum.2023-0764514